Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	4355	(paclitaxel or taxane or docetaxel or taxol or taxotere) and (analog or analogue or alternative) and design	US-PGPUB; USPAT	OR	ON	2004/10/15 09:07
L2	438	(paclitaxel or taxane or docetaxel or taxol or taxotere) and (synthetic adj2 (analog or analogue or alternative)) and design	US-PGPUB; USPAT	OR	ON	2004/10/15 09:27
L3	1	("6593374").PN.	US-PGPUB; USPAT	OR	OFF	2004/10/15 09:26
L4	132	(paclitaxel or taxane or docetaxel or taxol or taxotere) and (synthetic adj2 (derivative)) and design	US-PGPUB; USPAT	OR	ON	2004/10/15 09:31
L5	118	4 not 2	US-PGPUB; USPAT	OR	ON	2004/10/15 09:27
L6	551	(paclitaxel or taxane or docetaxel or taxol or taxotere) and drug adj design and computer	US-PGPUB; USPAT	OR	ON	2004/10/15 09:31
L10	6707	((703/1-11) or (702/19-29)).CCLS.	US-PGPUB; USPAT	OR	OFF	2004/10/15 09:33
L11	4	l6 and l10	US-PGPUB; USPAT	OR	OFF	2004/10/15 09:34
L12	45	l1 and l10	US-PGPUB; USPAT	OR	OFF	2004/10/15 09:34

```
=> d his

     (FILE 'HOME' ENTERED AT 08:22:33 ON 15 OCT 2004)

     INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, AQUALINE, ANABSTR, ANTE,
     AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,
     BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,
     CROPU, DISSABS, DDFB, DDFU, DGENE, ...' ENTERED AT 08:22:52 ON 15 OCT 2004
               SEA (PACLITAXEL OR TAXANE) AND (DESIGN OR MODEL OR MODELING) AN
                ---------
              479   FILE ADISCTI
               51   FILE ADISINSIGHT
               14   FILE ADISNEWS
                2   FILE AGRICOLA
                1   FILE ANABSTR
                3   FILE ANTE
                1   FILE AQUASCI
                7   FILE BIOBUSINESS
                4   FILE BIOCOMMERCE
               21   FILE BIOENG
              792   FILE BIOSIS
               11   FILE BIOTECHABS
               11   FILE BIOTECHDS
              115   FILE BIOTECHNO
               13   FILE CABA
              201   FILE CANCERLIT
              260   FILE CAPLUS
               13   FILE CEN
                2   FILE CONFSCI
               44   FILE DISSABS
               48   FILE DDFU
               18   FILE IMSDRUGNEWS
              105   FILE DRUGU
               38   FILE IMSRESEARCH
                3   FILE EMBAL
              452   FILE EMBASE
              109   FILE ESBIOBASE
               89   FILE FEDRIP
               36   FILE IFIPAT
               16   FILE JICST-EPLUS
               29   FILE LIFESCI
              319   FILE MEDLINE
                2   FILE NTIS
              199   FILE PASCAL
                7   FILE PHAR
                5   FILE PHARMAML
               35   FILE PHIN
              382   FILE PROMT
                8   FILE PROUSDDR
              222   FILE SCISEARCH
                1   FILE SYNTHLINE
              439   FILE TOXCENTER
             3451   FILE USPATFULL
              343   FILE USPAT2
               23   FILE WPIDS
               23   FILE WPINDEX
L1               QUE (PACLITAXEL OR TAXANE) AND (DESIGN OR MODEL OR MODELING) AN
                 ---------
                 SEA (PACLITAXEL OR TAXANE) AND (DESIGN OR (MOLECULAR (W) MODEL
                 ---------
```

```
              473   FILE ADISCTI
                5   FILE ADISINSIGHT
                2   FILE ADISNEWS
                1   FILE ANABSTR
                1   FILE ANTE
                1   FILE AQUASCI
                4   FILE BIOBUSINESS
                4   FILE BIOCOMMERCE
                2   FILE BIOENG
              127   FILE BIOSIS
                3   FILE BIOTECHABS
                3   FILE BIOTECHDS
               33   FILE BIOTECHNO
                2   FILE CABA
               56   FILE CANCERLIT
               89   FILE CAPLUS
               12   FILE CEN
                1   FILE CONFSCI
               16   FILE DISSABS
               15   FILE DDFU
                3   FILE IMSDRUGNEWS
               27   FILE DRUGU
                1   FILE EMBAL
              155   FILE EMBASE
               31   FILE ESBIOBASE
               49   FILE FEDRIP
                6   FILE IFIPAT
                5   FILE JICST-EPLUS
                2   FILE LIFESCI
               90   FILE MEDLINE
               64   FILE PASCAL
               16   FILE PHIN
              224   FILE PROMT
               65   FILE SCISEARCH
                1   FILE SYNTHLINE
              160   FILE TOXCENTER
             2167   FILE USPATFULL
              180   FILE USPAT2
                7   FILE WPIDS
                7   FILE WPINDEX
L2              QUE (PACLITAXEL OR TAXANE) AND (DESIGN OR (MOLECULAR (W) MODEL
                ---------

     FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 08:30:31 ON 15 OCT 2004
L3          461 S L2
L4          343 DUP REM L3 (118 DUPLICATES REMOVED)
L5          343 FOCUS L4 1-

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   191.85     199.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -21.00     -21.00

STN INTERN
```

L5 ANSWER 38 OF 343 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on Full Text

STN

AN 2004:245361 BIOSIS

DN PREV200400240212

TI Synthesis, **modeling**, and anti-tubulin activity of a D-seco **paclitaxel** analogue.

AU Barboni, Luciano [Reprint Author]; Giarlo, Guido; Ricciutelli, Massimo; Ballini, Roberto; Georg, Gunda I.; VanderVelde, David G.; Himes, Richard H.; Wang, Minmin; Lakdawala, Ami; Snyder, James P.

CS Dipartimento di Scienze Chimiche, Universita di Camerino, via S. Agostino 1, 62032, Camerino (MC), Italy
georg@ku.edu

SO Organic Letters, (February 19 2004) Vol. 6, No. 4, pp. 461-464. print.
ISSN: 1523-7060 (ISSN print).

DT Article

LA English

ED Entered STN: 6 May 2004
Last Updated on STN: 6 May 2004

AB We have previously described a model of **paclitaxel**-microtubule binding that led to the prediction that analogues of **paclitaxel** lacking any D ring could stabilize microtubules as well as **paclitaxel** if the substituent present at C4 did not have unfavorable steric interactions with the binding pocket. We report the synthesis of a 4-methyl **paclitaxel** analogue, compound 1, which bears this prediction out. Compound 1 is as potent as **paclitaxel** at microtubule stabilization in vitro; however, it has only about one-four-hundredth the cytotoxicity of **paclitaxel**.

AN 2002397778 EMBASE
TI Overcoming multidrug resistance in **taxane** chemotherapy.
AU Geney R.; Ungureanu I.M.; Li D.; Ojima I.
CS Dr. I. Ojima, Department of Chemistry, State Univ. of NY at Stony Brook, Stony Brook, NY 11794-3400, United States. IOJIMA@notes.cc.sunysb.edu
SO Clinical Chemistry and Laboratory Medicine, (2002) 40/9 (918-925).
Refs: 41
ISSN: 1434-6621 CODEN: CCLMFW
CY Germany
DT Journal; General Review
FS 016 Cancer
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
AB **Paclitaxel** (Taxol®) and docetaxel (Taxotere®) are currently two of the most important anticancer drugs in cancer chemotherapy. However, clinical treatment with these **taxane** agents often encounters undesirable side effects and multidrug resistance (MDR) caused by overexpression of P-glycoprotein (Pgp). Photoaffinity labeling of Pgp using photoreactive radiolabeled **paclitaxel** analogs along with molecular **modeling** has revealed a unique binding region for **paclitaxel** on the C-terminal half of Pgp. Highly efficient **taxane**-based MDR reversal agents (TRAs) have been developed. Extensive structure-activity relationship (SAR) studies have led to the development of new generation **taxanes** that possess 2-3 orders of magnitude higher potencies against human cancer cell lines expressing the MDR phenotype. One of these **taxanes**, SB-T-110131 (IDN5109, BAY59-8862), exhibits excellent activity against a variety of drug-sensitive and drug-resistant cancer cell lines as well as human tumor xenografts in mice. This **taxane** is orally active with excellent bioavailability, and is currently undergoing phase II human clinical trials, Novel **taxane**-antibody immunoconjugates have shown very promising results for tumor-specific delivery and release of an extremely cytotoxic **taxane**, wherein epidermal growth factor receptor is used as the specific antigen on the tumor surface of human squamous cancer xenograft in SCID mice.

TI Medicinal chemistry and chemical biology of new generation **taxane** antitumor agents

AU Ojima, Iwao; Geney, Raphael; Ungureanu, Ioana Maria; Li, Dansu

CS Chemistry Department, State University of New York at Stony Brook, Stony Brook, NY, 11794-3400, USA

SO IUBMB Life (2002), 53(4,5), 269-274
CODEN: IULIF8; ISSN: 1521-6543

PB Taylor & Francis Inc.

DT Journal; General Review

LA English

AB A review with refs. P-glycoprotein (P-GP)-based multidrug resistance (MDR) and undesirable side effects are significant drawbacks to the clin. use of **paclitaxel** and docetaxel. Extensive SAR studies of **taxanes** in these labs. led to the discovery of new generation **taxanes** that are highly active against not only drug-sensitive but also drug-resistant human cancer cell lines as well as tumor xenografts in mice. One of these second generation **taxanes**, SB-T-110131 (IDN5109), exhibited excellent pharmacol. profile in the preclin. studies and has been selected for clin. development (recoded as Bay 59-8862), which is currently in the phase II clin. trials. Bay 59-8862 is orally active with high bioavailability, showing excellent activity against a variety of drug-resistant tumors. "Advanced second generation **taxanes**" show essentially no difference in cytotoxicity against drug-resistant and drug-sensitive cell lines, virtually overcoming MDR. Photoaffinity labeling of P-GP using photoreactive radiolabeled **paclitaxel** analogs has disclosed the **paclitaxel**-binding domain of P-GP. Highly efficient **taxane**-based MDR reversal agents (TRAs) have also been developed, which can recover the cytotoxicity of **paclitaxel** to practically the original level against **paclitaxel**-resistant MDR expressing cancer cells. Highly promising results have emerged from the study of **taxane**-monoclonal antibody (MAb) immunoconjugates, which have been proved to specifically deliver extremely cytotoxic agents to tumor in an animal model.

RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT